Peptidylarginine deiminase (PAD): A promising target for chronic diseases treatment

P Mansouri, P Mansouri, E Behmard… - International Journal of …, 2024 - Elsevier
In 1958, the presence of citrulline in the structure of the proteins was discovered for the first
time. Several years later they found that Arginine converted to citrulline during a post …

Application of novel CAR technologies to improve treatment of autoimmune disease

A Cheever, CC Kang, KL O'Neill, KS Weber - Frontiers in Immunology, 2024 - frontiersin.org
Chimeric antigen receptor (CAR) T cell therapy has become an important treatment for
hematological cancers, and its success has spurred research into CAR T cell therapies for …

[HTML][HTML] Ревматоидный артрит как клинико-иммунологический синдром: фокус на серонегативный субтип заболевания

ЕЛ Насонов, АС Авдеева… - Научно-практическая …, 2023 - cyberleninka.ru
Ревматоидный артрит (РА)-наиболее частое иммуновоспалительное (аутоиммунное)
ревматическое заболевание (ИВРЗ), проявляющийся хроническим эрозивным …

Clinical presentation and treatment response in ACPA-negative rheumatoid arthritis

B Chevet, D Cornec - Joint Bone Spine, 2025 - Elsevier
Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation and
potential extra-articular manifestations. This review compares the presentation and …

Patients with ACPA-positive and ACPA-negative rheumatoid arthritis show different serological autoantibody repertoires and autoantibody associations with disease …

KY Cunningham, B Hur, VK Gupta, CA Arment… - Scientific reports, 2023 - nature.com
Patients with rheumatoid arthritis (RA) can test either positive or negative for circulating anti-
citrullinated protein antibodies (ACPA) and are thereby categorized as ACPA-positive …

Evaluating the docetaxel effect in an animal model of polyarthritis

OM Alghulami, GA Jasim, SY Jasim - Inflammopharmacology, 2024 - Springer
Rheumatoid arthritis (RA) is immune-mediated, inflammatory disease that affects synovial
joints, and characterized by inflammatory changes in synovial tissue, cartilage, bone, and …

Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody-and rheumatoid factor …

A Balanean, C Brown-Bickerstaff… - Journal of …, 2024 - becarispublishing.com
Aim: In rheumatoid arthritis (RA), seropositivity for both anticitrullinated protein antibody
(ACPA) and rheumatoid factor (RF) is associated with disease severity and therapeutic …

[PDF][PDF] Kevin Y. Cunningham, Benjamin Hur 2, 3, Vinod K. Gupta 2, 3, Courtney A. Arment 4, Kerry A. Wright 4, Thomas G. Mason 4, Lynne S. Peterson 4, Delamo I …

JM Davis III, J Sung - Scientific Reports, 2023 - sengenics.com
Results Study population and clinical/demographic characteristics. An overview of our study
design is presented in Fig. 1 A and is described as follows: This retrospective, observational …

[HTML][HTML] Патогенетическая взаимосвязь иммунологических нарушений при хроническом генерализованном пародонтите и ревматоидном артрите

ГВ Порядин, АН Захватов… - Архивъ внутренней …, 2022 - cyberleninka.ru
Патогенетическое единство механизмов прогрессирования хронического пародонтита
и ревматоидного артрита подтверждается общими звеньями иммуновоспалительных …

[PDF][PDF] Histopathological evaluation of docetaxel effects in treatment of rheumatoid arthritis induced in rat model

OM Alghulami, GA Jasim, SY Jasim - Al Mustansiriyah Journal of …, 2023 - iasj.net
Rheumatoid arthritis is an immunemediated condition that affects synovial joints. Synovial
tissue, cartilage, bone, and less frequently extra-articular structures which in turn experience …